2. Academic Validation
  3. Anticancer efficacy of hirsuteine against colorectal cancer by opposite modulation of wild-type and mutant p53

Anticancer efficacy of hirsuteine against colorectal cancer by opposite modulation of wild-type and mutant p53

  • Discov Oncol. 2023 May 31;14(1):84. doi: 10.1007/s12672-023-00688-1.
Yan Zhang # 1,  Tingting Guo # 1,  Shurong Li 1,  Zehao Ren 1,  Shan Gao 1,  Hao Lu 1,  Xuelan Ma 1,  Donghui Liu 1,  Yao Liu 2,  Dexin Kong 3,  Yuling Qiu 4
Affiliations

Affiliations

  • 1 Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, China.
  • 2 Department of Otorhinolaryngology Head and Neck Surgery, Tianjin First Central Hospital, Tianjin, China.
  • 3 Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, China. kongdexin@tmu.edu.cn.
  • 4 Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, China. qiuyuling@tmu.edu.cn.
  • # Contributed equally.
PMID: 37256374 DOI: 10.1007/s12672-023-00688-1
Abstract

Purpose: The present study aimed to explore the Anticancer activity of hirsuteine (HST), an indole alkaloid from the traditional Chinese herbal medicine Uncaria rhynchophylla, against colorectal Cancer (CRC) and the underlining mechanism.

Methods: MTT, colony formation, flow cytometry and MDC staining were conducted to confirm the antiproliferative effect of HST on human CRC cells harboring different p53 status. Protein expressions were evaluated by the Western blot analysis. p53 protein half-life and the interaction between p53 and MDM2 were investigated using cycloheximide (CHX)-chase assay and Co-immunoprecipitation (Co-IP), respectively. Transcriptional activity of p53 was examined by qRT-PCR and Chromatin immunoprecipitation (ChIP). Xenograft tumor in nude mice was created to evaluate in vivo Anticancer effect of HST against CRC.

Results: HST inhibited cell growth, arrested cell cycle and induced Autophagy, showing efficient Anticancer effects on CRC cells independent of p53 status. In HCT-8 cells, HST prolonged wtp53 half-life, and upregulated mRNA level of p21, suggesting that HST activated the p53 pathway through enhancement of wtp53 stability and transcriptional activity. Meanwhile in SW620 cells, HST induced MDM2-mediated proteasomal degradation of mutp53R273H, increased the DNA-binding ability of mutp53R273H at the p21 promoter, and upregulated mRNA levels of p21 and MDM2, demonstrating the depletion of mutp53R273H and restoration of its wild-type-like properties by HST. p53 knockdown by siRNA significantly impaired the growth inhibition of HST on HCT-8 and SW620 cells. Moreover, HST showed Anticancer effects in xenograft tumors, accompanied with an opposite regulation of wtp53 and mutp53 R273H in mechanism.

Conclusion: This study revealed the Anticancer efficacy of HST against CRC via opposite modulation of wtp53 and mutp53 R273H, indicating the potential of HST to be a CRC drug candidate targeting p53 signaling.

Keywords

Colorectal cancer; Hirsuteine; Mutant p53; Opposite modulation; Wild-type p53.

Figures
Products